2006 Annual Meeting | Stroke Prevention in 2006

Date Friday 04/07/06

Time 01:15 PM - 05:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) Mitchell S. Elkind, MD, MS, FAAN

Topic(s)

Learning Objectives Upon Completion:
Participants should be able to discuss and apply to stroke prevention the concepts of risk and risk stratification from the field of cardiovascular disease prevention; implement a systematic stroke prevention program; provide appropriate blood pressure reduction therapy for patients with history of stroke; discuss evidence linking markers such as high sensitivity C-reactive protein and intima-media thickness to risk of stroke; decide how to use statin and other medical therapies in stroke patients; apply the latest clinical trial results regarding antithrombotic agents in intracranial atherosclerosis; and provide a rational approach to the use of interventional techniques, including angioplasty and stenting, in patients with intracranial stenosis.

CME Available No CME available

Core Competencies Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident

Event Timeline
01:15 PM - 02:00 PM		What Can Cardiology Teach Us About Stroke Prevention? Jonathan Zaroff, MD
02:00 PM - 02:45 PM		Management of Blood Pressure After Stroke Philip B. Gorelick, MD, MPH, FAAN
02:45 PM - 03:00 PM		Break
03:00 PM - 03:45 PM		Biomarkers of Stroke Risk: Potential Modification by Statin and Other Therapies Mitchell S. Elkind, MD, MS, FAAN
03:45 PM - 04:30 PM		Intracranial Atherosclerosis: Diagnosis, Antithrombotic Therapy, and Interventional Approaches Barney J. Stern, MD, FAAN
04:30 PM - 05:00 PM		Questions and Answers

Faculty Disclosures
Philip B. Gorelick, MD, MPH, FAAN	Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AMGEN. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Gorelick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. Dr. Gorelick has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Thorek Memorial Hospital. Dr. Gorelick has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Thorek Memorial Hospital.
Mitchell S. Elkind, MD, MS, FAAN	Dr. Elkind has received personal compensation for serving as an employee of American Heart Association. Dr. Elkind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Atria Academy.
Barney J. Stern, MD, FAAN	Dr. Stern has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Foundation for Sarcoidosis Research. The institution of Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. The institution of Dr. Stern has received research support from NIH/NINDS. The institution of Dr. Stern has received research support from NIH/NINDS. The institution of Dr. Stern has received research support from NIH/NINDS. The institution of Dr. Stern has received research support from NIH/NINDS. Dr. Stern has received publishing royalties from a publication relating to health care.
Jonathan Zaroff, MD	No disclosure on file

��ɫ��

��ɫ��